课题基金 / 基金详情

Targeting Leukemia Stromal Interactions in AML

Targeting Leukemia Stromal Interactions in AML
靶向 AML 中的白血病基质相互作用
批准号:
8474710
负责人:
GEOFFREY L UY
金额:
$15.89万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-14 至 2015-06-30

项目摘要

项目成果

GEOFFREY L UY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This career development proposal is designed to provide training and support for the applicant to become an independent translational researcher focused on the biology and treatment of acute myeloid leukemia (AML). The goals of this proposal are to 1. To obtain didactic training in clinical research design, methodology for interpreting results of clinical research studies. 2. To develop clinical expertise in the treatment of AML and other hematologic malignancies. 3. To develop the "survival skills" necessary in clinical research including grant and manuscript writing, public speaking, navigating regulatory issues, and promoting effective collaborations. In AML, interaction of leukemic blasts with the bone marrow microenvironment may protect against spontaneous apoptosis and genotoxic stresses such as chemotherapy. The long term goal of this project is to identify and test therapies which target the protective effect of the marrow microenvironment. We hypothesize that by disrupting leukemia stromal interactions we will sensitize AML to the effects of cytotoxic chemotherapy. Although many candidate receptor-ligand pairs have been implicated, CXCR4 (expressed on normal and leukemic stem cells), and its ligand SDF-1 (expressed on BM stromal cells and osteoblasts) play a central role in stem cell homing and retention in the BM. We will test the ability of AMD3100, a small molecule inhibitor of CXCR4, to chemosensitize AML in a clinical trial entitled, "A phase l/ll study of AMD3100 plus mitoxantrone, etoposide, and cytarabine (AMD3100-I-MEC) in relapsed or refractory AML." We predict that like normal HSCs, AMD3100 will mobilize leukemic blasts in patients with AML. We will perform correlative studies to examine AML mobilization and alterations in CXCR4 / SDF-1 signaling in response to AMD3100. We will also continue to identify and test alternative pathways which mediate leukemia stromal interactions. RELEVANCE (See instructions): The goal of this proposal is to train an independent physician-scientist for a career as a translational researcher focused on the development of novel therapies for acute myeloid leukemia (AML). The proposed research plans to target the bone marrow microenvironment to improve the effectiveness of treatment of AML.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s11899-015-0255-4
发表时间: 2015-06
期刊: CURRENT HEMATOLOGIC MALIGNANCY REPORTS
影响因子: 2.9
作者: [Rashidi, Armin, Uy, Geoffrey L.]
通讯作者: Uy, Geoffrey L.
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature.
心脏同种异体移植物中发生的浆细胞瘤样移植后淋巴增殖性疾病:病例报告和文献综述。
DOI: 10.1200/jco.2011.39.5855
发表时间: 2012
期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子: --
作者: [Wang,Tzu-Fei, Klein,JonathanL, Woodard,PamelaK, Hassan,Anjum, Joseph,SusanM, Ewald,GregoryA, Uy,GeoffreyL]
通讯作者: Uy,GeoffreyL
Clinician Scientist in Leukemia
  • 批准号:
    10566421
  • 项目类别:
  • 资助金额:
    $13.28万
  • 财政年份:
    2023
  • 负责人:
    GEOFFREY L UY
  • 依托单位:
Project 2 - Targeted Therapies for T-ALL.
  • 批准号:
    10439622
  • 项目类别:
  • 资助金额:
    $32.9万
  • 财政年份:
    2013
  • 负责人:
    GEOFFREY L UY
  • 依托单位:
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
  • 批准号:
    8595788
  • 项目类别:
  • 资助金额:
    $33.99万
  • 财政年份:
    2013
  • 负责人:
    GEOFFREY L UY
  • 依托单位:
Project 2 - Targeted Therapies for T-ALL.
  • 批准号:
    10194401
  • 项目类别:
  • 资助金额:
    $27.62万
  • 财政年份:
    2013
  • 负责人:
    GEOFFREY L UY
  • 依托单位:
海外基金